0_1180 TATTOOS (Targeted Alpha Tumor Therapy and Other Oncological Solutions) offers the production of isotopically and radio-nuclidically pure radionuclides for radiopharmaceutical applications, revolutionizing cancer diagnosis and treatment. The facility plans to utilize a portion (100 μA) of the high-intensity (~2.4 mA), high-energy (590 MeV) proton beam from the ring cyclotron at Paul Scherrer Institute's High Intensity Proton Accelerator (HIPA) facility, combined with dedicated high-power spallation targets, to produce radionuclides.
The proton beam impinging on the target, results in a spallation reaction. Nonselective surface ionization or selective laser resonance ionization occurs inside the ionizer tube which is joul-heated. These ions are extracted by high voltage fields and guided towards the online mass separation using a dedicated dipole magnet. The mass-separated products will be chemically separated to achieve the desired nuclide from isobaric side bands and chemical impurities. The product will be radio-nuclidically and chemically pure enough to produce radiopharmaceuticals at the Center for Radiopharmaceutical Sciences towards preclinical and, in future, clinical applications.